282 related articles for article (PubMed ID: 16940075)
1. Natural variation can significantly alter the sensitivity of influenza A (H5N1) viruses to oseltamivir.
Rameix-Welti MA; Agou F; Buchy P; Mardy S; Aubin JT; Véron M; van der Werf S; Naffakh N
Antimicrob Agents Chemother; 2006 Nov; 50(11):3809-15. PubMed ID: 16940075
[TBL] [Abstract][Full Text] [Related]
2. Study of drug resistance of chicken influenza A virus (H5N1) from homology-modeled 3D structures of neuraminidases.
Wang SQ; Du QS; Chou KC
Biochem Biophys Res Commun; 2007 Mar; 354(3):634-40. PubMed ID: 17266937
[TBL] [Abstract][Full Text] [Related]
3. Neuraminidase amino acids 149 and 347 determine the infectivity and oseltamivir sensitivity of pandemic influenza A/H1N1 (2009) and avian influenza A/H5N1.
Yongkiettrakul S; Nivitchanyong T; Pannengpetch S; Wanitchang A; Jongkaewwattana A; Srimanote P
Virus Res; 2013 Aug; 175(2):128-33. PubMed ID: 23639424
[TBL] [Abstract][Full Text] [Related]
4. [Analysis of decrease in sensitivity in influenza A (H5N1) avian and human strains to neuraminidase inhibitors].
Reina J
Rev Esp Quimioter; 2008 Mar; 21(1):32-6. PubMed ID: 18443931
[TBL] [Abstract][Full Text] [Related]
5. Activity of the neuraminidase inhibitor A-315675 against oseltamivir-resistant influenza neuraminidases of N1 and N2 subtypes.
Abed Y; Nehmé B; Baz M; Boivin G
Antiviral Res; 2008 Feb; 77(2):163-6. PubMed ID: 17919743
[TBL] [Abstract][Full Text] [Related]
6. Insights from investigating the interaction of oseltamivir (Tamiflu) with neuraminidase of the 2009 H1N1 swine flu virus.
Wang SQ; Du QS; Huang RB; Zhang DW; Chou KC
Biochem Biophys Res Commun; 2009 Aug; 386(3):432-6. PubMed ID: 19523442
[TBL] [Abstract][Full Text] [Related]
7. Antiviral management of seasonal and pandemic influenza.
Hayden FG; Pavia AT
J Infect Dis; 2006 Nov; 194 Suppl 2():S119-26. PubMed ID: 17163384
[TBL] [Abstract][Full Text] [Related]
8. A new and rapid genotypic assay for the detection of neuraminidase inhibitor resistant influenza A viruses of subtype H1N1, H3N2, and H5N1.
Duwe S; Schweiger B
J Virol Methods; 2008 Nov; 153(2):134-41. PubMed ID: 18725246
[TBL] [Abstract][Full Text] [Related]
9. Assessing the development of oseltamivir and zanamivir resistance in A(H5N1) influenza viruses using a ferret model.
Hurt AC; Lowther S; Middleton D; Barr IG
Antiviral Res; 2010 Sep; 87(3):361-6. PubMed ID: 20603155
[TBL] [Abstract][Full Text] [Related]
10. Effect of neuraminidase inhibitor-resistant mutations on pathogenicity of clade 2.2 A/Turkey/15/06 (H5N1) influenza virus in ferrets.
Ilyushina NA; Seiler JP; Rehg JE; Webster RG; Govorkova EA
PLoS Pathog; 2010 May; 6(5):e1000933. PubMed ID: 20523902
[TBL] [Abstract][Full Text] [Related]
11. Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir.
Hurt AC; Barr IG; Hartel G; Hampson AW
Antiviral Res; 2004 Apr; 62(1):37-45. PubMed ID: 15026200
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the antiviral drug susceptibility of influenza viruses in Italy from 2004/05 to 2009/10 epidemics and from the recent 2009 pandemic.
Puzelli S; Facchini M; Di Martino A; Fabiani C; Lackenby A; Zambon M; Donatelli I
Antiviral Res; 2011 Jun; 90(3):205-12. PubMed ID: 21514326
[TBL] [Abstract][Full Text] [Related]
13. Neuraminidase inhibitor susceptibility network position statement: antiviral resistance in influenza A/H5N1 viruses.
Hayden F; Klimov A; Tashiro M; Hay A; Monto A; McKimm-Breschkin J; Macken C; Hampson A; Webster RG; Amyard M; Zambon M
Antivir Ther; 2005; 10(8):873-7. PubMed ID: 16430192
[TBL] [Abstract][Full Text] [Related]
14. Design of oseltamivir analogs inhibiting neuraminidase of avian influenza virus H5N1.
Rungrotmongkol T; Frecer V; De-Eknamkul W; Hannongbua S; Miertus S
Antiviral Res; 2009 Apr; 82(1):51-8. PubMed ID: 19428595
[TBL] [Abstract][Full Text] [Related]
15. Rapid quantitation of neuraminidase inhibitor drug resistance in influenza virus quasispecies.
Lackenby A; Democratis J; Siqueira MM; Zambon MC
Antivir Ther; 2008; 13(6):809-20. PubMed ID: 18839782
[TBL] [Abstract][Full Text] [Related]
16. Source of oseltamivir resistance in avian influenza H5N1 virus with the H274Y mutation.
Malaisree M; Rungrotmongkol T; Nunthaboot N; Aruksakunwong O; Intharathep P; Decha P; Sompornpisut P; Hannongbua S
Amino Acids; 2009 Oct; 37(4):725-32. PubMed ID: 19002747
[TBL] [Abstract][Full Text] [Related]
17. Another look at the molecular mechanism of the resistance of H5N1 influenza A virus neuraminidase (NA) to oseltamivir (OTV).
Mihajlovic ML; Mitrasinovic PM
Biophys Chem; 2008 Aug; 136(2-3):152-8. PubMed ID: 18584938
[TBL] [Abstract][Full Text] [Related]
18. Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice.
Ilyushina NA; Hoffmann E; Salomon R; Webster RG; Govorkova EA
Antivir Ther; 2007; 12(3):363-70. PubMed ID: 17591026
[TBL] [Abstract][Full Text] [Related]
19. Analogue inhibitors by modifying oseltamivir based on the crystal neuraminidase structure for treating drug-resistant H5N1 virus.
Du QS; Wang SQ; Chou KC
Biochem Biophys Res Commun; 2007 Oct; 362(2):525-31. PubMed ID: 17707775
[TBL] [Abstract][Full Text] [Related]
20. Evolution of drug resistance in multiple distinct lineages of H5N1 avian influenza.
Hill AW; Guralnick RP; Wilson MJ; Habib F; Janies D
Infect Genet Evol; 2009 Mar; 9(2):169-78. PubMed ID: 19022400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
